These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3172677)

  • 21. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.
    Uusitupa MI; Niskanen LK; Siitonen O; Voutilainen E; Pyörälä K
    Circulation; 1990 Jul; 82(1):27-36. PubMed ID: 2194696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria.
    Kapelrud H; Bangstad HJ; Dahl-Jørgensen K; Berg K; Hanssen KF
    BMJ; 1991 Sep; 303(6804):675-8. PubMed ID: 1833011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
    Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
    J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma insulin and serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetic and non-diabetic subjects.
    Laakso M; Pyörälä K; Voutilainen E; Marniemi J
    Am J Epidemiol; 1987 Apr; 125(4):611-21. PubMed ID: 3548333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
    Kappelle PJ; Dallinga-Thie GM; Dullaart RP;
    Biochim Biophys Acta; 2010 Jan; 1801(1):89-94. PubMed ID: 19800983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Glycemic control and lipoprotein profile in type I diabetes mellitus].
    García Pascual L; Mesa Manteca J; Obiols Alfonso G; Chacón Castro P; Campos Barreda F; Simó Canonge R
    Med Clin (Barc); 1991 Nov; 97(17):645-9. PubMed ID: 1762457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma insulin, serum lipids and lipoproteins in gall stone disease in non-insulin dependent diabetic subjects: a case control study.
    Laakso M; Suhonen M; Julkunen R; Pyörälä K
    Gut; 1990 Mar; 31(3):344-7. PubMed ID: 2182400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study.
    Bruno G; Merletti F; Biggeri A; Bargero G; Prina-Cerai S; Pagano G; Cavallo-Perin P
    Diabetologia; 2006 May; 49(5):937-44. PubMed ID: 16525840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls.
    Gouni-Berthold I; Giannakidou E; Faust M; Berthold HK; Krone W
    Atherosclerosis; 2005 Dec; 183(2):336-41. PubMed ID: 16285997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men.
    Bagdade JD; Subbaiah PV
    Diabetes; 1989 Oct; 38(10):1226-30. PubMed ID: 2507376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative and qualitative derangement of apolipoprotein B-containing lipoproteins as a risk factor for diabetic macroangiopathy in nonobese NIDDM subjects.
    Harano Y; Kageyama A; Nakao Y; Hara Y; Suzuki M; Sato A; Ikebuchi M; Shinozaki K; Tsushima M
    Diabetes; 1996 Jul; 45 Suppl 3():S31-4. PubMed ID: 8674886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.
    Jiang R; Schulze MB; Li T; Rifai N; Stampfer MJ; Rimm EB; Hu FB
    Diabetes Care; 2004 Aug; 27(8):1991-7. PubMed ID: 15277429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of dyslipidemia among patients with diabetes mellitus in Jilin Province communities].
    He H; Li Y; Wang C; Tang Y; Yan Z; Lv L; Zhang H; Liu F; Gu Y; Meng T; Guan C; Yu Y; Liu Y
    Wei Sheng Yan Jiu; 2014 Sep; 43(5):743-8. PubMed ID: 25438527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein levels in normolipidemic non-insulin-dependent diabetes mellitus.
    Horng YC; Wei JS; Chang RS; Huang HS; Huang MJ; Huang BY
    J Formos Med Assoc; 1992 Jun; 91(6):590-4. PubMed ID: 1358344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.
    Sacks FM; Hermans MP; Fioretto P; Valensi P; Davis T; Horton E; Wanner C; Al-Rubeaan K; Aronson R; Barzon I; Bishop L; Bonora E; Bunnag P; Chuang LM; Deerochanawong C; Goldenberg R; Harshfield B; Hernández C; Herzlinger-Botein S; Itoh H; Jia W; Jiang YD; Kadowaki T; Laranjo N; Leiter L; Miwa T; Odawara M; Ohashi K; Ohno A; Pan C; Pan J; Pedro-Botet J; Reiner Z; Rotella CM; Simo R; Tanaka M; Tedeschi-Reiner E; Twum-Barima D; Zoppini G; Carey VJ
    Circulation; 2014 Mar; 129(9):999-1008. PubMed ID: 24352521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein pattern in long-term diabetes of an at least 35 years' duration. Results of the Erfurt Study.
    Schauer UJ; Panzram G; Pissarek D; Rühling K; Winkler L; Lundershausen R
    Klin Wochenschr; 1988 Aug; 66(15):694-8. PubMed ID: 3172677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of coronary heart disease with serum lipid and apolipoprotein concentrations in long-term diabetes. Results of the Erfurt study.
    Schauer UJ; Pissarek D; Panzram G
    Acta Diabetol Lat; 1989; 26(1):35-42. PubMed ID: 2501960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum lipids and apolipoproteins in relation to glycaemic control and diabetic nephropathy in long-term survivors of diabetes: results of the Erfurt Study.
    Schauer UJ; Pissarek D; Lundershausen R; Rühling K; Winkler L; Panzram G
    Exp Clin Endocrinol; 1988 Mar; 92(3):280-6. PubMed ID: 3267003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.